BCTX - BriaCell Therapeutics Corp
3.86
-0.150 -3.886%
Share volume: 186,040
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$4.01
-0.15
-0.04%
View ratios
| Fiscal Date | 01-31-2024 | 04-30-2024 | 07-31-2024 | 10-31-2024 | 01-31-2025 | 04-30-2025 | 07-31-2025 | 10-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
| Report Date | 03-18-2024 | 06-14-2024 | 12-16-2024 | 12-16-2024 | 03-12-2025 | 06-16-2025 | 10-16-2025 | 12-11-2025 | |
| Assets | |||||||||
| Total Assets | 12.231 M | 6.203 M | 5.872 M | 10.414 M | 9.364 M | 17.002 M | 21.650 M | 13.075 M | |
| Current Assets | 11.742 M | 5.530 M | 3.654 M | 8.219 M | 7.163 M | 14.785 M | 19.927 M | 11.348 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 7.372 M | 7.462 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 6.245 M | 935.694 K | 862.089 K | 5.792 M | 5.014 M | 12.460 M | 10.494 M | 2.714 M | |
| Total Non-current Assets | 2.000 | 2.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 388.175 K | 365.336 K | 342.497 K | 319.658 K | 296.819 K | 273.980 K | |
| Other Assets | 489.088 K | 673.274 K | 1.830 M | 1.830 M | 1.858 M | 1.897 M | 1.426 M | 1.453 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 12.231 M | 6.203 M | 5.872 M | 10.414 M | 9.364 M | 17.002 M | 21.650 M | 13.075 M | |
| Total liabilities | 20.549 M | 12.436 M | 8.557 M | 6.701 M | 6.137 M | 5.061 M | 4.316 M | 3.725 M | |
| Total current liabilities | 3.924 M | 6.758 M | 7.461 M | 4.989 M | 5.231 M | 4.331 M | 3.978 M | 3.318 M | |
| Accounts Payable | 3.924 M | 6.758 M | 7.461 M | 4.989 M | 5.231 M | 4.331 M | 3.978 M | 3.318 M | |
| Other liabilities | 16.624 M | 5.679 M | 1.096 M | 1.713 M | 905.838 K | 730.012 K | 337.672 K | 406.873 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 16.624 M | 5.679 M | 1.096 M | 1.713 M | 905.838 K | 730.012 K | 337.672 K | 406.873 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -8.073 M | -5.965 M | -2.382 M | 4.043 M | 3.603 M | 12.415 M | 17.881 M | 9.978 M | |
| Common stock | 69.592 M | 69.592 M | 72.166 M | 82.041 M | 85.451 M | 94.023 M | 101.740 M | 101.740 M | |
| Retained earnings | -85.945 M | -84.230 M | -85.444 M | -91.246 M | -97.537 M | -103.664 M | -111.756 M | -119.953 M |